





## Joint HMA/EMA multi-stakeholder workshop on submission predictability

25 September 2024, 09:00 – 13:30 (CET/CEST) Virtual meeting/ EMA, Amsterdam

The event will gather representatives from national competent authorities, the European Medicines Agency, and industry stakeholders. The workshop aims to raise awareness and foster mutual understanding of how changing submission dates for initial centralised Marketing Authorisation Applications (MAAs) affect EMA and network resources, workload, and expertise planning. Additionally, it will provide a platform for industry stakeholders to share best practices for submissions and discuss strategies to enhance the predictability of MAAs submissions and overall network resource management.

In particular, the objectives of this workshop are to:

- To showcase data and trends on submissions predictability problem statement
- To share best practices approach for submission of initial marketing authorisation applications
- To create awareness of the impact from a resource perspective when changing submission dates
- To strengthen cooperation and communication amongst stakeholders
- To discuss strategies to improve submission predictability

## Multi-stakeholder workshop on submission predictability draft agenda

*Chaired by Francesca Day (EMA – Head of Therapeutic Area department) and Aimad Torqui (Head of Division – MEB.NL)* 

## 25 September 2024, 09:00 - 13:30 (CEST)

| 08:45 | Joining and technical checks   |        |  |
|-------|--|--------|--|
|       |  |        |  |
| 09:00 | Welcome and opening speech   |        |  |
|       | Welcome and opening remarks by EMA Executive Director & Head of Agency (BfArM) 5 min |        |  |
|       | Emer Cooke (EMA) and Karl Broich (BfArM)   | 10 min |  |
| 09:15 | EMA Statistics on Submission Predictability and problem statement                    |        |  |
|       | <b>Presentation</b><br>Enrico Tognana (EMA)  | 20 min |  |
| 09:35 | Best Practice approach using current guidance  |        |  |
|       | <b>Presentation</b><br>Francesca Day   | 20 min |  |
| 09:55 | Views & concerns from Member States on Submission Predictability                     |        |  |
|       | <b>Presentation</b><br>Ingrid Landberg (MPA-SE) and Günter Waxenecker (AGES-AT)      | 40 min |  |
| 10:35 | Update on Rapporteur appointments  |        |  |
|       | Presentation   |        |  |
|       | Alberto Gañán Jiménez (EMA)  | 10 min |  |
| 10:45 | Q&A session  |        |  |
|       |  | 15 min |  |
| 11:00 | Slido questions for industry   |        |  |

| 11:05 | Coffee break   |                     |
|-------|--|---------------------|
|       |  | 15 min              |
| 11:20 | Industry representatives present their viewpoint on submi predictability | ssion               |
|       |  | 20 min              |
| 11:40 | Case studies: Innovators, Generics and Biosimilars                       |                     |
|       |  | 60 min              |
| 12:40 | Slido questions for industry   |                     |
|       |  | 5 min               |
| 12:45 | Panel Discussion   |                     |
|       | Q&A Exchange of Ideas – how can we improve submission predic             | tability?<br>35 min |
| 13:20 | Closing remarks  |                     |
|       | Wrap up and next steps<br>Francesca Day (EMA)                            | 10 min              |

5 min